KRAS and pericardial effusion: In conclusion, EGFR and KRAS mutation frequencies are not evenly distributed among different metastatic sites, with a relative increase in EGFR mutation frequency and a decrease in KRAS mutation frequency in pleural and pericardial effusions compared to primary tumors, which could have implications for patient management.